Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline
combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant
Prolactinomas
Phase:
N/A
Details
Lead Sponsor:
Zhebao Wu
Collaborators:
Beijing Tiantan Hospital Chinese PLA General Hospital First Affiliated Hospital of Fujian Medical University First Affiliated Hospital of Wenzhou Medical University First Hospital of China Medical University Huashan Hospital Peking Union Medical College Hospital Xinqiao Hospital of Chongqing